DE602007005231D1 - Bioresorbierbare zusammensetzung mit kontrollierter freisetzung - Google Patents

Bioresorbierbare zusammensetzung mit kontrollierter freisetzung

Info

Publication number
DE602007005231D1
DE602007005231D1 DE602007005231T DE602007005231T DE602007005231D1 DE 602007005231 D1 DE602007005231 D1 DE 602007005231D1 DE 602007005231 T DE602007005231 T DE 602007005231T DE 602007005231 T DE602007005231 T DE 602007005231T DE 602007005231 D1 DE602007005231 D1 DE 602007005231D1
Authority
DE
Germany
Prior art keywords
ceramic
pharmaceutical composition
preparation
controlled
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007005231T
Other languages
English (en)
Inventor
Niklas Axen
Hans Lennernaes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lidds AB
Original Assignee
Lidds AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lidds AB filed Critical Lidds AB
Publication of DE602007005231D1 publication Critical patent/DE602007005231D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602007005231T 2006-03-14 2007-03-14 Bioresorbierbare zusammensetzung mit kontrollierter freisetzung Active DE602007005231D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600361 2006-03-14
PCT/EP2007/002250 WO2007104549A2 (en) 2006-03-14 2007-03-14 Bioresorbable controlled-release composition

Publications (1)

Publication Number Publication Date
DE602007005231D1 true DE602007005231D1 (de) 2010-04-22

Family

ID=36602790

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007005231T Active DE602007005231D1 (de) 2006-03-14 2007-03-14 Bioresorbierbare zusammensetzung mit kontrollierter freisetzung

Country Status (18)

Country Link
US (1) US8999389B2 (de)
EP (1) EP1996160B8 (de)
JP (1) JP5216601B2 (de)
KR (1) KR101378174B1 (de)
CN (1) CN101431984B (de)
AT (1) ATE460154T1 (de)
AU (1) AU2007224651B8 (de)
CA (1) CA2644429C (de)
DE (1) DE602007005231D1 (de)
DK (1) DK1996160T3 (de)
ES (1) ES2342123T3 (de)
HK (1) HK1129061A1 (de)
IL (1) IL193973A (de)
MX (1) MX2008011606A (de)
PL (1) PL1996160T3 (de)
RU (1) RU2405537C2 (de)
WO (1) WO2007104549A2 (de)
ZA (1) ZA200807881B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL181834A (en) 2006-04-02 2011-04-28 Iscar Ltd Cutting head and adaptor
EP2376135B1 (de) * 2008-11-27 2015-05-27 Lidds Ab Verwendung von carboxymethylcellulose zur kontrolle der auswerfbarkeit und erstarrungszeit von zusammensetzungen aus ein oder mehr bioresorbieraren keramikmaterialien
WO2010093285A1 (en) * 2009-02-12 2010-08-19 Aduro Material Ab Composition comprising biodegradable carrier for controlled drug delivery
AU2014372690B2 (en) * 2013-12-23 2019-10-03 Bcn Peptides, S.A. Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis
CN114010628A (zh) 2015-06-04 2022-02-08 克里蒂泰克公司 紫杉烷颗粒及其用途
SG11201808125RA (en) 2016-04-04 2018-10-30 Crititech Inc Methods for solid tumor treatment
SG11201902825RA (en) 2016-10-17 2019-05-30 Lidds Ab A new method for producing calcium sulphate hemihydrate with unique properties
AU2018279634A1 (en) 2017-06-09 2019-10-31 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
EP3615004A1 (de) 2017-06-14 2020-03-04 Crititech, Inc. Verfahren zur behandlung von lungenerkrankungen
WO2019070850A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
RU2683255C1 (ru) * 2018-03-06 2019-03-27 Федеральное государственное бюджетное учреждение науки Институт химии твердого тела Уральского отделения Российской академии наук Биоактивный композиционный материал для замещения костных дефектов и способ его получения
WO2019170912A1 (en) 2018-03-09 2019-09-12 Lidds Ab Bioresorbable controlled-release compositions with sting modulating molecules

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797758A (en) * 1972-06-16 1974-03-19 Giulini Gmbh Geb Method of producing finely dispersed alpha calcium sulfate hemihydrate
JP2702953B2 (ja) 1988-01-30 1998-01-26 オリンパス光学工業株式会社 薬液含浸セラミックス
US5055307A (en) 1988-12-29 1991-10-08 Asahi Kagaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5614206A (en) * 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
US8333996B2 (en) 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
US6132463A (en) 1995-05-19 2000-10-17 Etex Corporation Cell seeding of ceramic compositions
AU734691B2 (en) * 1996-10-16 2001-06-21 Life Science Enterprises, Inc. Bioceramic compositions
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6030635A (en) * 1998-02-27 2000-02-29 Musculoskeletal Transplant Foundation Malleable paste for filling bone defects
GB0020610D0 (en) 2000-08-21 2000-10-11 Dytech Corp Ltd Uses of porous carriers
US6730324B2 (en) 2001-04-20 2004-05-04 The University Of British Columbia Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
SE522749C2 (sv) * 2002-03-04 2004-03-02 Cerbio Tech Ab Ytbeläggningsförfarande, ytbelagd anordning och biokompatibel ytbeläggning
PL1680089T3 (pl) 2003-10-22 2014-03-31 Lidds Ab Kompozycja zawierająca biodegradowalną ceramikę hydratującą do kontrolowanego dostarczania leków

Also Published As

Publication number Publication date
IL193973A0 (en) 2009-09-22
RU2008140519A (ru) 2010-04-20
EP1996160A2 (de) 2008-12-03
MX2008011606A (es) 2008-09-22
CN101431984A (zh) 2009-05-13
JP2009529554A (ja) 2009-08-20
ATE460154T1 (de) 2010-03-15
DK1996160T3 (da) 2010-07-05
AU2007224651B8 (en) 2011-10-27
US20090118215A1 (en) 2009-05-07
CA2644429A1 (en) 2007-09-20
KR101378174B1 (ko) 2014-03-27
AU2007224651A1 (en) 2007-09-20
EP1996160B8 (de) 2010-05-12
PL1996160T3 (pl) 2010-09-30
US8999389B2 (en) 2015-04-07
WO2007104549A3 (en) 2007-11-08
EP1996160B1 (de) 2010-03-10
AU2007224651A8 (en) 2011-10-27
RU2405537C2 (ru) 2010-12-10
IL193973A (en) 2012-07-31
ZA200807881B (en) 2009-10-28
WO2007104549A2 (en) 2007-09-20
AU2007224651B2 (en) 2011-10-13
ES2342123T3 (es) 2010-07-01
JP5216601B2 (ja) 2013-06-19
WO2007104549A8 (en) 2007-12-13
KR20080108128A (ko) 2008-12-11
CA2644429C (en) 2014-07-29
HK1129061A1 (en) 2009-11-20
CN101431984B (zh) 2013-07-10

Similar Documents

Publication Publication Date Title
DE602007005231D1 (de) Bioresorbierbare zusammensetzung mit kontrollierter freisetzung
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
BRPI0715893A2 (pt) composto de azetidina e uso para a preparaÇço de um medicamento para a prevenÇço ou tratamento de distérbios distÍmicos ou do sono
WO2006044504A8 (en) Cgrp receptor antagonists
WO2006029153A3 (en) Monocyclic anilide spirolactam cgrp receptor antagonists
MY156822A (en) Indole derivatives as s1p1 receptor agonists
RS51563B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ROOSUVASTATIN CALCIUM
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
HN2008001530A (es) Compuestos de amino pirimidina 2,6- sustituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
BRPI0717570B8 (pt) composição farmacêutica sólida adequada para administração oral, seu uso e seu processo de produção
UY29459A1 (es) Forma cristalina ortorrómbica del maleato de asenapina y su uso en el tratamiento de trastornos mentales
WO2008112159A3 (en) Monocyclic anilide spirolactam cgrp receptor antagonists
CL2007001530A1 (es) Compuestos derivados de tiazol, inhibidores de fbpasa; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de diabetes mellitus tipo i, ii y iii, desequilibrio de glucosa en ayunas, desequilibrio en la tolerancia de la glucosa y complicaciones de la diabetes.
WO2006031491A3 (en) Tricyclic anilide spirolactam cgrp receptor antagonists
CL2008003067A1 (es) Compuesto 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida, modulador de receptores nicotinicos alfa-7; proceso de preparacion; composicion farmaceutica y su proceso de preparacion; y su uso en el tratamiento de trastornos psicoticos, intelectuales, inflamatorios.
WO2006004741A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
BRPI0620566B8 (pt) composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip
WO2008048801A3 (en) Phenylalkylamino carbamate compositions
WO2007072201A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
DK2018169T3 (da) Anvendelse af 4,17-beta-dihydroxyandrost-4-en-3-on til behandling af cancer
CL2011000061A1 (es) Compuestos derivados de tetrahidrocinolinas, inhibidores de la 11-beta-hsd1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, obesidad, trastornos de ingestion de comida o dislipidemia.
EA200970378A1 (ru) Композиции фенилалкилкарбамата
WO2005115392A8 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
WO2006047196A3 (en) Cgrp receptor antagonists

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: LENNERNAES, HANS, 756 52 UPPSALA, SE

Inventor name: AXEN, NIKLAS, 740 21 JAERLASA, SE

8364 No opposition during term of opposition